2022 was an active year in Canadian patent law. Claim fees were introduced for the first time; changes were made to regulations providing remedies for excessive pricing of patented.
The Federal Court of Appeal (FCA) dismissed an appeal by Pharmascience from a decision of the Federal Court. which found Canadian Patent No. 2,760,802 (802 Patent) valid and infringed.